10:22 AM EST - Oncolytics Biotech Inc : Announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous cell anal carcinoma, a setting with no U.S. Food and Drug Administration -approved treatment options. Previous analysis from this cohort has focused on second-line or later SCAC patients. Oncolytics Biotech Inc
shares N.ONCY are trading off $0.01 at $0.96.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7788555409258106
